{
  "generated": "2025-11-06T07:07:38.675176+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/behavioral/inositol-slee-gen-0016/sleep/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "SLEE-GEN-0016_01",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/inositol-slee-gen-0016-01",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0016-01",
      "citation": "SLEE-GEN-0016_01 (2016); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/inositol-slee-gen-0016-01; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "SLEE-GEN-0016_02",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/inositol-slee-gen-0016-02",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0016-02",
      "citation": "SLEE-GEN-0016_02 (2017); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/inositol-slee-gen-0016-02; Adverse Events: None reported."
    },
    {
      "study_id": "SLEE-GEN-0016_03",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "sleep_journal",
      "outcome": "rem_quality",
      "population": "Adults with rem quality concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/inositol-slee-gen-0016-03",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0016-03",
      "citation": "SLEE-GEN-0016_03 (2018); Journal: sleep_journal; Design: randomized controlled trial; Population: Adults with rem quality concerns; Outcome: rem_quality; DOI: 10.1234/inositol-slee-gen-0016-03; Adverse Events: Transient headache."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/inositol-slee-gen-0016-01",
      "study_ids": [
        "SLEE-GEN-0016_01"
      ],
      "primary_study_id": "SLEE-GEN-0016_01",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0016-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/inositol-slee-gen-0016-02",
      "study_ids": [
        "SLEE-GEN-0016_02"
      ],
      "primary_study_id": "SLEE-GEN-0016_02",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0016-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/inositol-slee-gen-0016-03",
      "study_ids": [
        "SLEE-GEN-0016_03"
      ],
      "primary_study_id": "SLEE-GEN-0016_03",
      "url": "https://doi.org/10.1234/inositol-slee-gen-0016-03"
    }
  ],
  "manifest_hash": "sha256:7e93204efd4df7a6b122929cb0ced8dd8cac27b0abf3594d90cf72a0df748a05"
}
